Cytokinetics (CYTK) Insider Exercise and Sale: 2,000 Shares

Rhea-AI Filing Summary

Insider transactions by Dr. Malik Fady Ibraham, EVP Research & Development of Cytokinetics (CYTK), are reported on Form 4. On 08/19/2025 he exercised 2,000 non‑qualified stock options at an exercise price of $10.60 and concurrently sold 2,000 shares at $38.31. After these transactions he beneficially owned 140,610 shares. The filing shows 9,105 option shares remaining exercisable from the option series.

Positive

• Exercise executed at $10.60, indicating option strike was significantly below sale price
• Reporting timely and signed by attorney-in-fact, reflecting compliance with Section 16 disclosure

Negative

• Sale of 2,000 shares reduced direct holdings from 142,610 to 140,610
• No disclosure of a 10b5-1 plan specifics beyond the checked box, so plan details are not provided

Insights

Financial Analyst

TL;DR: Officer exercised options cheaply and sold shares same day, realizing a cash difference but leaving substantial ownership.

The transaction shows a typical option exercise-and-sell-throughs (likely to cover tax or diversify) where 2,000 options were exercised at $10.60 and the resulting shares were sold at $38.31 on the same date, realizing the spread. Post-transaction beneficial ownership remains material at 140,610 shares, and 9,105 option shares remain exercisable. The activity is a routine liquidity event by an insider rather than a corporate governance change.

Corporate Governance Expert

TL;DR: Insider sale occurred but reporting complies with Section 16 disclosure; no governance red flags in filing.

The Form 4 is complete for the reported transactions and is signed by an attorney-in-fact, indicating proper execution. The filing notes the reporter is an officer (EVP R&D). The immediate exercise and sale pattern aligns with standard insider practices; there is no indication of undisclosed related-party transactions or departures. Material governance impact appears neutral.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Research & Development

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2025		M		2,000	A	$10.6	142,610	D
Common Stock	08/19/2025		S		2,000	D	$38.31	140,610	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$10.6	08/19/2025		M			2,000	03/28/2017	02/28/2027	Common Stock	2,000	$0	9,105	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did CYTK insider Malik Fady Ibraham report on Form 4?

On 08/19/2025 he exercised 2,000 options at $10.60 and sold 2,000 common shares at $38.31.

How many CYTK shares does the reporting person own after the transactions?

The filing reports beneficial ownership of 140,610 shares following the transactions.

Are there remaining exercisable options reported for the insider?

Yes, the filing shows 9,105 option shares beneficially owned and exercisable following the reported transactions.

Did the filing indicate the transaction was made under a 10b5-1 plan?

Yes, the filer checked the box indicating the transaction was made pursuant to a Rule 10b5-1(c) plan.

What is the reporting person's role at Cytokinetics?

The reporting person is listed as EVP Research & Development at Cytokinetics.